Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 9/20 | 0.43 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.42 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.42 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28180755 | 0.98 | FDPS (0.41) | FDPSGGPS1CES2LPAR1LPAR3 | |
| SCHEMBL27548532 | 0.90 | — | — | |
| SCHEMBL5768532 | 0.85 | FDPS (0.50) | FDPSGGPS1CES2SMPD1TSHR | |
| SCHEMBL8528159 | 0.85 | FDPS (0.50) | FDPSGGPS1CES2SMPD1TSHR | |
| SCHEMBL5672619 | 0.85 | FDPS (0.50) | FDPSGGPS1CES2SMPD1TSHR | |
| SCHEMBL4952756 | 0.85 | FDPS (0.50) | FDPSGGPS1CES2SMPD1TSHR | |
| SCHEMBL5176670 | 0.85 | FDPS (0.50) | FDPSGGPS1CES2SMPD1TSHR | |
| SCHEMBL11572196 | 0.85 | FDPS (0.50) | FDPSGGPS1CES2SMPD1TSHR | |
| SCHEMBL2669436 | 0.85 | FDPS (0.50) | FDPSGGPS1CES2SMPD1TSHR | |
| SCHEMBL2346921 | 0.85 | FDPS (0.50) | FDPSGGPS1CES2SMPD1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916513-B2 | Dioxirane compounds and uses thereof | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2014-12-23 | — | — | US | disclosed |
| US-20140187467-A1 | DIOXIRANE COMPOUNDS AND USES THEREOF | CRESTLINE DIRECT FINANCE, L.P. | 2014-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187467-A1 | DIOXIRANE COMPOUNDS AND USES THEREOF | DUOX2, DECR2, SCO2 | FDPS 2218/4885GGPS1 2382/4885CES2 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.